1. Home
  2. NLSP vs TSI Comparison

NLSP vs TSI Comparison

Compare NLSP & TSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NLSP
  • TSI
  • Stock Information
  • Founded
  • NLSP 2015
  • TSI 1987
  • Country
  • NLSP Switzerland
  • TSI United States
  • Employees
  • NLSP N/A
  • TSI N/A
  • Industry
  • NLSP Biotechnology: Pharmaceutical Preparations
  • TSI Investment Managers
  • Sector
  • NLSP Health Care
  • TSI Finance
  • Exchange
  • NLSP Nasdaq
  • TSI Nasdaq
  • Market Cap
  • NLSP 12.4M
  • TSI 234.6M
  • IPO Year
  • NLSP 2021
  • TSI N/A
  • Fundamental
  • Price
  • NLSP $2.20
  • TSI $4.89
  • Analyst Decision
  • NLSP
  • TSI
  • Analyst Count
  • NLSP 0
  • TSI 0
  • Target Price
  • NLSP N/A
  • TSI N/A
  • AVG Volume (30 Days)
  • NLSP 265.8K
  • TSI 106.8K
  • Earning Date
  • NLSP 07-22-2025
  • TSI 01-01-0001
  • Dividend Yield
  • NLSP N/A
  • TSI 7.46%
  • EPS Growth
  • NLSP N/A
  • TSI N/A
  • EPS
  • NLSP N/A
  • TSI N/A
  • Revenue
  • NLSP N/A
  • TSI N/A
  • Revenue This Year
  • NLSP N/A
  • TSI N/A
  • Revenue Next Year
  • NLSP N/A
  • TSI N/A
  • P/E Ratio
  • NLSP N/A
  • TSI N/A
  • Revenue Growth
  • NLSP N/A
  • TSI N/A
  • 52 Week Low
  • NLSP $1.30
  • TSI $4.48
  • 52 Week High
  • NLSP $15.59
  • TSI $4.87
  • Technical
  • Relative Strength Index (RSI)
  • NLSP 43.99
  • TSI 47.25
  • Support Level
  • NLSP $2.06
  • TSI $4.87
  • Resistance Level
  • NLSP $2.33
  • TSI $4.91
  • Average True Range (ATR)
  • NLSP 0.25
  • TSI 0.04
  • MACD
  • NLSP -0.07
  • TSI -0.00
  • Stochastic Oscillator
  • NLSP 7.84
  • TSI 28.57

About NLSP NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

About TSI TCW Strategic Income Fund Inc.

Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.

Share on Social Networks: